• By ICR Secretariat
  • Posted Thursday, September 12, 2019

Amgen puts its KRAS hopes on 'Navy Seals' team of drug hunters

https://www.biopharmadive.com/news/amgen-kras-navy-seals-team-lung-cancer-drug/561633/

Amgen's never moved faster.

In late August of last year, the first patient enrolled in a small clinical study received treatment with a cancer drug now known as AMG 510. Just over nine months later, Amgen executives were at oncology's premier annual meeting presenting results from the Phase 1 portion of testing.